PTGX holder plans Rule 144 sale of 20,000 shares

PTGX shareholder plans to sell 20,000 shares of common stock under Rule 144 through Morgan Stanley Smith Barney on or about 02/06/2026, with the shares listed on NASDAQ.

Rhea-AI Filing Summary

PTGX shareholder plans to sell 20,000 shares of common stock under Rule 144 through Morgan Stanley Smith Barney on or about 02/06/2026, with the shares listed on NASDAQ.

The planned sale has an aggregate market value of $1,673,672.00. Shares outstanding were 62,515,666; this is a baseline figure, not the amount being sold. The seller acquired the 20,000 shares the same day by exercising a stock option and paid the purchase price in cash.

FAQ

What does the PTGX Form 144 filing disclose about planned share sales?

The filing shows a PTGX shareholder plans to sell 20,000 common shares under Rule 144. The transaction is routed through Morgan Stanley Smith Barney, with an aggregate market value of $1,673,672 and the shares traded on NASDAQ.

How many PTGX shares are involved in the Rule 144 sale and what is their value?

The notice covers 20,000 PTGX common shares with an aggregate market value of $1,673,672. This amount reflects the planned sale reported in the filing and is separate from the 62,515,666 total shares outstanding of the issuer.

How were the PTGX shares being sold under Rule 144 acquired?

The 20,000 PTGX shares were acquired via a stock option exercise on 02/06/2026. The filing states the seller obtained these common shares directly from the issuer and fully paid for them in cash on the same date as the acquisition.

Which broker is handling the PTGX Rule 144 share sale?

The planned PTGX share sale is being handled by Morgan Stanley Smith Barney LLC Executive Financial Services. The broker’s listed address is 1 New York Plaza, 8th Floor, New York, NY 10004, and the shares are identified for trading on NASDAQ.

What does the PTGX seller represent about non-public information in this Rule 144 notice?

By signing the notice, the seller represents they do not know any material adverse information about PTGX’s current or prospective operations that has not been publicly disclosed, consistent with the representation language required in a Rule 144 filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/06/2026 - 04:04 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001553338
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	PROTAGONIST THERAPEUTICS, INC.
SEC File Number	001-37852
Address of Issuer	7707 Gateway Boulevard, Suite 140 Newark CALIFORNIA 94560-1160
Phone	(510) 474-0170
Name of Person for Whose Account the Securities are To Be Sold	WILLIAM D WADDILL
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	20000	1673672.00	62515666	02/06/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/06/2026	Stock Option Exercise	Issuer			20000	02/06/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	02/06/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ William Duryea Waddill
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)